INSP Inspire Medical Systems, Inc.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1609550 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.2%
TTM net income YoY126.0%
TTM EPS YoY129.5%
Revenue 3-yr CAGR15.6%
Net income 3-yr CAGR—
Margins
Gross margin86.2%
Operating margin1.8%
Net margin11.4%
FCF margin11.1%
EBITDA margin3.9%
Returns
ROE13.5%
ROA11.4%
ROIC (approx.)2.6%
Asset turnover1.00x
Leverage & solvency
Liabilities / assets13.2%
Debt / equity0.00x
Current ratio6.45x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $911.98M | $802.80M |
| Cost of revenue | $133.22M | $122.99M |
| Gross profit | $778.76M | $679.82M |
| R&D expense | $103.17M | $114.13M |
| SG&A expense | $624.64M | $529.61M |
| Operating income | $50.95M | $36.08M |
| Interest expense | $137,000 | $22,000 |
| Pretax income | $65.70M | $58.45M |
| Income tax | -$79.72M | $4.94M |
| Net income | $145.42M | $53.51M |
| EBITDA | $64.91M | $42.63M |
| EPS (basic) | 4.95 | 1.80 |
| EPS (diluted) | 4.89 | 1.75 |
| Weighted avg. shares (diluted) | 29.76M | 30.54M |
| Balance sheet | ||
| Cash & equivalents | $104.81M | $150.15M |
| Short-term investments | $203.46M | $295.40M |
| Receivables | $119.69M | $93.07M |
| Inventory | $145.29M | $80.12M |
| Current assets | $583.65M | $630.81M |
| PP&E, net | $97.87M | $71.92M |
| Total assets | $907.32M | $808.38M |
| Current liabilities | $96.06M | $88.50M |
| Total liabilities | $126.16M | $118.69M |
| Shareholders' equity | $781.16M | $689.70M |
| Shares outstanding | 28.58M | 29.74M |
| Cash flow statement | ||
| Operating cash flow | $116.98M | $130.25M |
| Capital expenditure | $38.50M | $39.12M |
| Free cash flow | $78.48M | $91.12M |
| Investing cash flow | $21.45M | -$113.12M |
| Financing cash flow | -$183.45M | -$52.39M |
| Depreciation & amortization | $13.96M | $6.55M |
| Stock-based compensation | $130.26M | $116.01M |
| Share buybacks | $175.02M | $0 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.